Revolution Medicines, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Revolution Medicines, Inc. (RVMD) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $39.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-05
- Revolution Medicines, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $55.78M, a 415.55% increase year-over-year.
- Revolution Medicines, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$16.74M, a 1180.63% decline year-over-year.
- Revolution Medicines, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $54.60M, a 198.42% increase year-over-year.
- Revolution Medicines, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $45.29M, a 340.56% increase year-over-year.
- Revolution Medicines, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $112.27M, a 410.65% increase from fiscal 2024.
- Revolution Medicines, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $21.98M, a 49.88% increase from fiscal 2023.
- Revolution Medicines, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $14.67M, a 876.56% increase from fiscal 2022.
- Revolution Medicines, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $1.50M, a 82.78% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $55.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $39.04M 10-Q · filed 2026-08-05 | $93.65M derived: sum of 3 quarters · filed 2026-08-05 | $138.94M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$16.74M 10-Q · filed 2026-05-06 | $37.87M derived: sum of 2 quarters · filed 2026-05-06 | $83.16M derived: sum of 3 quarters · filed 2026-05-06 | $93.98M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $54.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $99.90M derived: sum of 2 quarters · filed 2026-02-25 | $110.72M derived: sum of 3 quarters · filed 2026-08-05 | $112.27M 10-K · filed 2026-02-25 |
| 2025-09-30 | $45.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $56.11M derived: sum of 2 quarters · filed 2026-08-05 | $57.66M 10-Q · filed 2025-11-05 | $75.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $10.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $12.37M 10-Q · filed 2026-08-05 | $30.67M derived: sum of 3 quarters · filed 2026-08-05 | $40.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.55M 10-Q · filed 2026-05-06 | $19.85M derived: sum of 2 quarters · filed 2026-05-06 | $30.13M derived: sum of 3 quarters · filed 2026-05-06 | $44.79M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $18.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $28.58M derived: sum of 2 quarters · filed 2026-02-25 | $43.24M derived: sum of 3 quarters · filed 2026-02-25 | $21.98M 10-K · filed 2026-02-25 |
| 2024-09-30 | $10.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $24.95M derived: sum of 2 quarters · filed 2025-11-05 | $3.69M 10-Q · filed 2025-11-05 | -$2.60M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $14.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$6.59M 10-Q · filed 2025-08-06 | -$12.88M derived: sum of 3 quarters · filed 2026-02-25 | -$5.31M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$21.26M 10-Q · filed 2025-05-07 | -$27.55M derived: sum of 2 quarters · filed 2026-02-25 | -$19.97M derived: sum of 3 quarters · filed 2026-02-25 | -$4.84M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$6.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.29M derived: sum of 2 quarters · filed 2026-02-25 | $16.42M derived: sum of 3 quarters · filed 2026-02-25 | $14.67M 10-K · filed 2026-02-25 |
| 2023-09-30 | $7.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $22.71M derived: sum of 2 quarters · filed 2024-11-06 | $20.96M 10-Q · filed 2024-11-06 | $17.99M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $15.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $13.38M 10-Q · filed 2024-08-07 | $10.42M derived: sum of 3 quarters · filed 2025-02-26 | $9.12M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$1.75M 10-Q · filed 2024-05-08 | -$4.72M derived: sum of 2 quarters · filed 2025-02-26 | -$6.01M derived: sum of 3 quarters · filed 2025-02-26 | $1.86M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$4.26M derived: sum of 2 quarters · filed 2025-02-26 | $3.62M derived: sum of 3 quarters · filed 2025-02-26 | $1.50M 10-K · filed 2025-02-26 |
| 2022-09-30 | -$1.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $6.58M derived: sum of 2 quarters · filed 2023-11-06 | $4.47M 10-Q · filed 2023-11-06 | $8.21M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $7.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $5.76M 10-Q · filed 2023-08-08 | $9.51M derived: sum of 3 quarters · filed 2024-02-26 | $11.24M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$2.11M 10-Q · filed 2023-05-08 | $1.63M derived: sum of 2 quarters · filed 2024-02-26 | $3.36M derived: sum of 3 quarters · filed 2024-02-26 | $5.41M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $3.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $5.48M derived: sum of 2 quarters · filed 2024-02-26 | $7.52M derived: sum of 3 quarters · filed 2024-02-26 | $8.72M 10-K · filed 2024-02-26 |
| 2021-09-30 | $1.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $3.78M derived: sum of 2 quarters · filed 2022-11-07 | $4.98M 10-Q · filed 2022-11-07 | $4.79M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $2.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $3.24M 10-Q · filed 2022-08-09 | $3.05M derived: sum of 3 quarters · filed 2023-02-27 | $6.81M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $1.20M 10-Q · filed 2022-05-09 | $1.01M derived: sum of 2 quarters · filed 2023-02-27 | $4.77M derived: sum of 3 quarters · filed 2023-02-27 | $7.02M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$191.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $3.57M derived: sum of 2 quarters · filed 2023-02-27 | $5.82M derived: sum of 3 quarters · filed 2023-02-27 | $4.86M 10-K · filed 2023-02-27 |
| 2020-09-30 | $3.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $6.01M derived: sum of 2 quarters · filed 2021-11-10 | $5.05M 10-Q · filed 2021-11-10 | $6.46M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $2.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $1.29M 10-Q · filed 2021-08-11 | $2.70M derived: sum of 3 quarters · filed 2022-02-28 | $7.38M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$963.00K 10-Q · filed 2021-05-10 | $447.00K derived: sum of 2 quarters · filed 2022-02-28 | $5.13M derived: sum of 3 quarters · filed 2022-02-28 | $5.47M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $6.09M derived: sum of 2 quarters · filed 2022-02-28 | $6.43M derived: sum of 3 quarters · filed 2022-02-28 | $6.04M 10-K · filed 2022-02-28 |
| 2019-09-30 | $4.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $5.02M derived: sum of 2 quarters · filed 2020-11-12 | $4.63M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $338.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$53.00K 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | -$391.00K 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | $1.91M 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |